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Objective:  To  conduct  a cost-utility  analysis  on  an  integrated  healthcare  model  comprising  an  assigned
internist  and  a hospital  liaison  nurse  for patients  with  multimorbidity,  compared  to  a conventional
reactive  healthcare  system.
Methods:  A  cluster  randomised  clinical  trial  was  conducted.  The  model  consisted  of a reference  internist
and  a liaison  nurse,  who  aimed  to  improve  coordination  and  communication  between  levels  and  to
enhance  continuity  of  care  after  hospitalisation.  We  recorded  sociodemographic  data,  diagnoses  and  cor-
responding  clinical  categories,  functional  status,  use  of  healthcare  resources  and  quality  of life.  Data  were
collected  by  reviewing  electronic  medical  records  and  administering  questionnaires.  We  performed  uni-
variate and  multivariate  analyses  both  for utilities  and total  costs.  Bootstrapping  methods  were applied
to calculate  the  conﬁdence  ellipses  of  incremental  costs  and  efﬁciency.
Results:  We  recruited  a  total of  140 patients.  The  model  assessed  was  not found  to be efﬁcient  in general.
We  found  an incremental  cost  of D  1,035.90  and  an  incremental  beneﬁt  of −0.0762  QALYs  for the  initiative
compared  to  standard  care  after  adjusting  for the  main  variables.  However,  the  subgroup  of  patients  under
80 years  of  age  with  three  or more  clinical  categories  resulted  in  an  89%  cost  saving  in the simulations.
Conclusions:  The  integrated  model  was  not  suitable  for all study  patients.  However,  the  subgroup  analysis
identiﬁed  a  narrow  target  population  that should  be analysed  in future  studies.
©  2016  SESPAS.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Análisis  de  coste-utilidad  de  un  modelo  de  atención  integrada  a  pacientes
pluripatológicos  basado  en  un  ensayo  clínico
alabras clave:
omorbilidad
nálisis de coste-beneﬁcio
sistencia sanitaria integrada
nsayo clínico
r  e  s  u  m  e  n
Objetivo:  Evaluar  en términos  de  coste-utilidad  un  modelo  de  atención  integrada  a  pacientes  pluripa-
tológicos  basado  en  el internista  de  referencia  y  la  enfermera  de  enlace  hospitalario,  comparado  con  un
sistema  asistencial  convencional  reactivo  por  episodios.
Métodos:  Se realizó  un ensayo  clínico  aleatorizado  por  conglomerados.  La  intervención  se  basó  en un
internista  de  referencia  y  una  enfermera  de  enlace  hospitalario.  Ambos  trabajaron  en la  coordinación
y  la comunicación  entre  niveles  y en  la mejora  de  la  continuidad  de  cuidados  después  de  un ingreso.
Se  recogieron  datos  sociodemográﬁcos  y los  diagnósticos  con  sus  correspondientes  categorías  clínicas,
así  como  el estado  funcional,  la utilización  de  recursos  y la  calidad  de  vida.  Se  utilizaron  los  registros
electrónicos  médicos  existentes  y  cuestionarios  administrados.  Se  realizaron  análisis  univariados  y  mul-
tivariados  tanto  para  las  utilidades  como  para  los costes  totales.  Mediante  bootstrapping  se  calcularon  las
elipses  de  conﬁanza  de  los costes  incrementales  y la  eﬁciencia.
Resultados:  Se  incluyeron  en  el estudio  140 pacientes.  En  general,  la intervención  no  resultó  eﬁciente.
El  coste  incremental  de  la  intervención  frente  al modelo  convencional  fue  de 1035,90  D y la  efectividad
incremental  fue  de  −0,0762  an˜os  de  vida  ajustados  por  calidad,  al  ajustar  los  datos  por las  variables  más
relevantes.  Sin  embargo,  el  subgrupo  de  pacientes  menores  de 80 an˜os  con  tres  o  más  categorías  clínicas
ahorró  costes  en  el  89%  de  las  simulaciones.
nciónConclusiones:  La  interve
obstante,  el análisis  de  subgru
ser  analizada  en  estudios  futur
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The number of patients with multimorbidity is becoming so
igh that if it is not properly addressed, care for them will soon
ecome unsustainable.1,2 Two common characteristics are that
heir health problems cannot be cured and that their health
tatus is progressively deteriorating.3 In order to improve their
are, Yán˜ez-Cadena et al.4 have underlined the need to adopt a
ystematic approach to design programs that combine organi-
ational strategies and self-care. The provision of care to these
atients is an excellent opportunity for innovation in healthcare
ntegration based on the current healthcare structure, avoid-
ng fragmentation of healthcare, but without excessive structural
hanges.5
In January 2011, in the Basque Country (Spain), the integrated
ealthcare organization was established for bringing together
he primary and specialized care.6 In this context, an integrated
odel was introduced, based around an assigned internist and
 hospital liaison nurse. However, the effectiveness of multi-
aceted interventions for preventing the functional decline of
lderly patients is still controversial.7 In a review of the lit-
rature, Smith et al.8 underlines the need to develop efﬁcient
nterventions for patients with multimorbidity. To our knowl-
dge, there are no published studies having demonstrated that
hey are really more efﬁcient than usual care, and none assess-
ng their economic impact in Spain. Generally, it is assumed
hat these models increase the efﬁciency and the quality of care
rovided to patients, and also that they are efﬁcient. However,
here is a lack of systematic evaluation, including the assessment
f the relative costs and beneﬁts. High quality evidence from
ell-designed studies is required to supporting decision making
n the long-term funding of particular types of integrated care
nterventions.9
The objective of this study was to assess whether an integrated
are model for patients with multimorbidity, based on an assigned
nternist and a hospital liaison nurse, is efﬁcient compared to the
urrent system based on episodic reactive care.
ethods
tudy design
We  carried out a cost-utility analysis based on a prospective and
ulti-center cluster randomized trial, with two  groups of patients
ith multimorbidity, randomized by doctor’s list. Cluster random-
zation trials are experiments in which intact social units or clusters
f individuals rather than independent individuals are randomly
llocated to intervention groups. As the organizational change was
aturally applied at the cluster level we applied in our study this
esign to avoid treatment group contamination. This approach did
ot incorporate blinding and therefore its results showed a lower
evel of evidence.10 The participating providers were the seven pri-
ary healthcare centers of the Goierri-Alto Urola health district,
ogether with the referral hospital, Zumarraga hospital. Patients’
andomization was based on the primary care clinicians’ random-
zation carried out before this study started. Patients were recruited
onsecutively from each health center when they met  three inclu-
ion criteria: to have at least one hospitalization episode during
he past year, to be classiﬁed as multimorbid patients according
he criteria of the Junta de Andalucía2 and to have given writ-
en informed consent. Exclusion criteria included patient refusal
o participate in the study, living in a nursing home or being on
emodialysis. A total of 140 patients were recruited, 70 in each
roup. The duration of the intervention period in this study was
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Intervention
The intervention was focused on the management of care for
these patients. That is, we did not change the type of clinical
care provided. The intervention consisted on the implementa-
tion of an integrated health care model for multimorbid patients
based on improving communication between primary care and
hospital professionals. Speciﬁcally, intervention group (IG) multi-
morbid patients were managed by the primary care team (general
practitioner and nurse) with the support of a reference internist
and a liaison nurse. Reference internist gave direct support in
the Health Centre and ensured smooth and ﬂexible communi-
cation with primary care doctors. Moreover, every time patients
with multimorbidity went to the hospital they were seen by their
assigned internist, regardless of the required service. As soon as
the patient was identiﬁed as being multimorbid the liaison nurse
carried out a complete assessment (clinical, functional, psychoso-
cial and quality of life). This information was aimed to enhance
continuity of care after hospitalization in coordination with pri-
mary care to avoid re-hospitalizations. Furthermore, the liaison
nurse provided health education to improve self-management of
each speciﬁc disease. In the control group (CG), patients received
usual care corresponding to routine practice, with no strengthen-
ing of the coordination between primary and hospital-based care.
The protocol was approved by the local ethics committee.
Study variables
We collected data from medical records on the following demo-
graphic and clinical variables: age, sex, referral health center, and
clinical diagnoses, as well as the corresponding clinical categories.
Data about resources consumption during 12 months included
hospital admissions, emergency department attendances, visits to
specialists, visits to primary care doctors and nurses and diagnostic
tests recorded in the Osakidetza-Basque Health Service data base.
In addition, we  recorded Barthel Index scores,11 as a measure of
functional status regarding basic activities of daily living at base-
line; and EuroQol (EQ-5D) utility scores,12 as a measure of quality
of life at baseline and the end of the study period, that is, before
and 1 year after implementation of the new model.
Estimation of cost and quality-adjusted life years
We calculated for each patient cost and quality-adjusted life
years (QALYs) during the 12 months follow-up. For estimating
costs, we  multiplied the rates of resources use by the unit cost
obtained from the Accounting Department (stay day: D 414.00/day;
emergency department consultation: D 140.69; 24-hour health
clinic consultation: D 39.01; specialized consultation: D 141.04; pri-
mary care consultation: D 23.11; home care visit: D 69.32; CT scan:
D 77.63; and ultrasound scan: D 33.46). The cost of the interven-
tion per attended patient (D 341.68) was calculated by dividing the
salary of the liaison nurse by the number of patients under her care.
For the estimation of QALYs, we  considered scores on the EQ-5D
questionnaire before and 1 year after introduction of the inter-
vention. The efﬁciency for each period of the intervention was
calculated with area under the curve analysis, assuming linear
interpolation between consecutive time points and taking into
account the follow-up period for all patients included.13
Statistical analysisFirst, we tested the randomness of the samples, univariate anal-
ysis was performed using the chi-squared test or Fisher’s exact
test to identify any socio-demographic or diagnostic variables that
3 Sanit. 2016;30(5):352–358
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Table 1
Characteristics of the study groups at the start of the study.
Control group Intervention group p
N (%) N (%)
Total 70 (50.00) 70 (50.00)
Sex
Male 45 (64.29) 50 (71.43)
Female 25 (35.71) 20 (28.57) 0.366
Age
<80  years 35 (50.00) 39 (55.71)
≥80 years 35 (50.00) 31 (44.29) 0.498
Number of chronic conditions categories
2 38 (54.29) 37 (52.86)
≥3 32 (45.71) 33 (47.14) 0.865
Baseline Barthel Index score
Independent (≥60) 58 (82.86) 57 (81.43)
Dependent (<60) 12 (17.14) 13 (18.57) 0.825
Baseline EQ-5D utility score
<0 9 (12.86) 6 (8.57)
0  to 0.5 8 (11.43) 8 (11.43)
>0.5 to 0.75 26 (37.14) 30 (42.86)
>0.75 to 1 27 (38.57) 26 (37.14) 0.824
Follow-up
Entire year completed 53 (75.71) 48 (68.57)54 I. Lanzeta et al. / Gac 
iffered between the two groups that had been selected randomly.
 signiﬁcance level of 5% was set.
Second, intervention results in terms of resource consumption
uring the study period were described using absolute and relative
requencies as well as mean values for the intervention and control
roups. The analysis of the difference between mean values was
arried out using Student t-test and Chi-squared test was used for
ategorical data.
Third, univariate analysis was carried out to identify the vari-
bles that were associated with efﬁciency and total costs. As costs
nd QALYs are generally skewed data, nonparametric tests were
sed in order to compare median values for different variables
ategories. However, cost-utility analysis is based on the differ-
nce in mean cost and the difference in mean effect. In fact, that
ccurs because the mean is important from both budgetary and
ocial perspective. Therefore, t-test or ANOVA variance analysis
ere also carried out with the aim of estimating signiﬁcance on
ean differences between variable categories. In addition, univari-
te generalized linear models (GLM) were also applied in order to
how its results compared to the commonly used approaches.
All variables that show association in the one by one analysis
ere involved in the subsequent multivariate analysis. Group (IG
s. CG) variable was included in all the ﬁnal models, given that the
urpose of the study was to assess the effect of the intervention
n the efﬁciency and costs, adjusting for other variables that could
nﬂuence them. Baseline Barthel Index scores were not included
n the multivariate analysis to avoid collinearity with utilities, as
easured by EQ-5D. Multivariate analysis was carried out using
oth ordinary least square regressions (OLS) and GLM. Finally joint
nalysis of costs and efﬁciency was carried out using Seemingly
nrelated Regression (SUR). The same independent variables were
ncluded in the multivariate analysis both for QALYs and for total
osts in order to simplify the interpretation. The estimation of the
ncremental cost-effectiveness ratio (ICER), which describes the
dditional cost of each extra QALY, was calculated as the ratio of
he coefﬁcients of the variable group in the multiple regressions of
ost and efﬁciency.14 In a second model using SUR subgroup analy-
is was performed considering also the interactions of the variables
ge and number of clinical categories with the variable group.
Once analysis of the original data had been performed at the
atient level, we analyzed the overall distribution using a non-
arametric bootstrapping method given that the sample size was
mall. This method makes it possible to estimate the uncertainty of
he ﬁnal decision in different samples assuming that initial samples
f both groups represented the real population. For this purpose,
e carried out 1,000 simulations, in which new samples of patients
ere created by selecting patients (with replacement). The boot-
trapping method allowed estimating the 95% conﬁdence intervals
f the intervention effects both in costs and QALYs for the analyzed
ubgroups and calculating the conﬁdence ellipses for the ICER using
he variance-covariance matrix estimated in the joint analysis of
osts and efﬁciency.14,15
esults
Between April 2011 and February 2012, we recruited a total of
40 patients with multimorbidity with a mean age of 78.2 years.
rom them 72% completed an entire year, 25% died, and in the
emaining cases (3%), follow-up was stopped as they were admit-
ed to residential care homes. We  found no signiﬁcant differences
etween the two groups prior to the intervention as summarized
n Table 1. In both groups, more than half of the patients had diag-
oses in two clinical categories. Overall, 17.8% of patients obtained
aseline Barthel Index scores below 60 and hence were classiﬁed
s dependent.Died 17 (24.29) 18 (25.71)
Stopped for other reasons 0 (0.00) 4 (5.71) 0.118
The description of resource consumption carried out by the
control and intervention group is shown in Table 2. No statistical
differences were found between the two groups.
Table 3 and Table 4 show which variables had a direct impact
on cost and utility of the intervention. We  can see there are clear
differences in QALYs by sex, age, number of clinical categories, and
baseline Barthel Index and EQ-5D utility scores but none of the vari-
ables considered had an impact on the total costs when comparing
mean values through usual methodology. Results are similar when
univariate GLM methods were applied for mean comparison. The
crude values indicate that the intervention increased the mean cost
per patient by D 1,093.1, compared to that for the controls. More-
over, the efﬁciency in patients from the intervention group was
0.0553 QALY lower.
When analyzing the intervention effect adjusted by other rel-
evant variables (sex, age, number of categories and baseline
EQ5D), the results showed similar conclusions as intervention arm
remained more expensive and less efﬁcient, both using OLS and
GLM (Table 5). In the joint multivariate statistical analysis (Table 5)
using the simple model, we  found an incremental cost of D 1,035.9
and an incremental beneﬁt of −0.0762 QALYs for the intervention
compared to usual care, after adjusting for sex, patient age, number
of clinical categories and EQ-5D utility score at the beginning of the
study. When the interactions of the age and number of clinical cat-
egories with the variable group were included (Table 5) we could
realize that considering the subgroups of patients under 80 years
of age and with chronic health problems in three or more clinical
categories, mean costs were lower among those in the IG but with-
out statistical signiﬁcance. Nonetheless, the beneﬁt was  also lower
as was the case for all the subgroups analyzed.
In the cost-utility plane (Figure 1), we  can see the results cor-
responding to the bootstrapping method applied to the original
sample and the subgroup of those under 80 years old with three
or more categories of chronic conditions. Considering the observed
variability, we calculated the likelihood of the intervention being
cost saving across the simulations performed. The subgroup of peo-
ple under 80 years of age with conditions in three or more clinical
categories resulted cost saving in 89% of the simulations whereas
this percentage was  15% for the original sample.
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Table  2
Description of the main resource consumption for each group during the 1-year
study period.
Control group Intervention group p
N (%) N (%)
Hospitalizations
0 37 (52.90) 27 (38.60)
1  14 (20.00) 20 (28.60)
2  13 (18.60) 12 (17.10)
>2 6 (8.60) 11 (15.70) 0.248
Media (SD) 0.89 (1.20) 1.24 (1.58) 0.135
Length of stay
0  37 (52.90) 27 (38.60)
1-7 11 (15.70) 14 (20.00)
8-14 8 (11.40) 9 (12.90)
>14 14 (20.00) 20 (28.60) 0.385
Media (SD) 7.20 (11.43) 9.47 (12.34) 0.261
Emergency room
0 13 (18.60) 18 (25.70)
1  22 (31.40) 17 (24.30)
2  12 (17.10) 17 (24.30)
>2 23 (32.90) 18 (25.70) 0.404
Media (SD) 2.16 (2.08) 1.90 (1.88) 0.447
Home care
0 24 (34.30) 29 (41.40)
1-7 22 (31.40) 16 (22.90)
8-14 8 (11.40) 8 (11.40)
15-30 9 (12.90) 12 (17.10)
>30 7 (10.00) 5 (7.10) 0.703
Media (SD) 11.59 (23.92) 9.46 (16.10) 0.537
Specialist consultations
0  28 (40.00) 18 (25.70)
1-2 15 (21.40) 26 (37.10)
3-5 22 (31.40) 19 (27.10)
>5 5 (7.10) 7 (10.00) 0.128
Media (SD) 2.26 (2.86) 2.40 (2.32) 0.746
Primary care consultations
<10 18 (25.70) 22 (31.40)
10-25 26 (37.10) 27 (38.60)
26-40 11 (15.70) 14 (20.00)
>40 15 (21.40) 7 (10.00) 0.297
Media (SD) 22.70 (17.87) 20.04 (16.00) 0.358
SD: standard deviation.
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Figure 1. Cost-utility plane of the intervention under study in the entire sample and
Table 3
Association between the total costs incurred in the 1-year study period and the study var
Median (q1; q3) pa
Group
Control 2,545.8 (1,109.2; 7,553.4) 
Intervention 4,492.5 (1,691.6; 9,991.7) 0.258 
Sex
Male  3,544.9 (1,432.6; 9,991.7) 
Female 2,511.1 (1,316.4; 7,622.8) 0.330 
Age
<80  years 3,250.4 (1,529.7; 8,322.3) 
≥80  years 2,999.8 (1,230.9; 8,294.0) 0.548 
Number of chronic condition categories
2 2,580.4 (1,198.4; 7,553.4) 
≥3  4,483.4 (1,624.4; 9,991.7) 0.195 
Baseline Barthel Index score
Independent (≥60) 2,843.1 (1,399.9; 8,564.2) 
Dependent (<60) 4,662.8 (909.7; 8,294.0) 0.884 
Baseline EQ-5D utility score
<  0 1,272.9 (369.7; 7,756.1) 
0  to 0.5 6,615.7 (2,370.1; 9,888.2) 
>0.5  to 0.75 3,438.8 (1,620.0; 10,296.5) 
>0.75 to 1 2,197.0 (1,369.7; 6,806.4) 0.148 
GLM: generalized linear models; q1: value for the ﬁrst quartile or percentile 25; q3: value
a Median comparison using log-rank test and Kruskal-Wallis.
b Mean comparison using t-test and ANOVA variance analysis.
c Generalized linear model assuming gamma  family with log link.in  the subsample of patients under 80 years of age with three or more categories of
chronic conditions.
Discussion
The evaluated integrated healthcare intervention for patients
with multimorbidity was not found to be efﬁcient. However, the
statistical analysis revealed that in the patients under 80 years of
age with a high level of comorbidity (conditions in three or more
clinical categories), the intervention decreased costs in 89% of the
simulations, although the difference was not statistically signiﬁcant
in that subgroup either. The lack of efﬁciency was  observed across
all the subgroups analyzed which was to be expected, given the
frailty and risk factors, of the target population.
Our intervention can be described in terms of the Kaiser
Permanente model as a case management and our target pop-
ulation being included in the top 5% of the Kaiser pyramid.16,17Regarding the subgroups analyzed, we  consider that patients with
multimorbidity who have only two clinical categories of condi-
tions, regardless of age, correspond to the high-risk patients with
a lower level of complexity in the Kaiser pyramid, and hence
iables.
Total costs
Mean (SD) pb GLMc
4,973.3 (5,486.4)
6,066.4 (5,514.8) 0.242 0.245
5,839.1 (5,816.8)
4,845.9 (4,783.3) 0.321 0.300
5,794.6 (6,005.5)
5,211.8 (4,918.7) 0.534 0.529
4,964.0 (5,197.6)
6,161.3 (5,820.6) 0.201 0.203
5,527.7 (5,655.8)
5,483.8 (4,876.1) 0.971 0.971
3,828.9 (3,996.1)
6,609.9 (5,131.4) 0.131
6,347.2 (6,073.8) 0.084
4,795.2 (5,265.4) 0.240 0.444
 for the third quartile or percentile 75; SD: standard deviation.
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Table 4
Association between the efﬁciency in the 1-year study period and the study variables.
Quality-adjusted life years
Median (q1; q3) pa Mean (SD) pb GLMc
Group
Control 0.6251 (0.1381; 0.8391) 0.5235 (0.3886)
Intervention 0.5834 (0.0861; 0.8518) 0.493 0.4682 (0.4003) 0.410 0.410
Sex
Male  0.6276 (0.1486; 0.8771) 0.5440 (0.3859)
Female 0.5324 (0.0093; 0.6696) 0.016 0.3925 (0.3955) 0.035 0.050
Age
<80  years 0.6585 (0.2179; 0.9095) 0.5734 (0.3670)
≥80  years 0.5193 (0.0313; 0.7814) 0.012 0.4080 (0.4077) 0.013 0.016
Number of chronic condition categories
2 0.7061 (0.2937; 0.8935) 0.6162 (0.3536)
≥3  0.2976 (0.0617; 0.6757) <0.001 0.3592 (0.3954) <0.001 <0.001
Baseline Barthel Index score
Independent (≥60) 0.6757 (0.2923; 0.8771) 0.5996 (0.3406)
Dependent (<60) −0.0102 (−0.1196; 0.0591) <0.001 −0.0002 (0.2134) <0.001 <0.001
Baseline EQ-5D utility score
<0 −0.0696 (−0.2719; −0.0172) −0.1399 (0.1504)
0  to 0.5 0.1486 (0.0593; 0.3394) 0.1958 (0.1972) <0.001
>0.5  to 0.75 0.5861 (0.1311; 0.6636) 0.4565 (0.2695) <0.001
>0.75  to 1 0.8935 (0.7976; 1.0000) <0.001 0.8076 (0.2723) <0.001 <0.001
GLM: generalized linear models; q1: value for the ﬁrst quartile or percentile 25; q3: value for the third quartile or percentile 75; SD: standard deviation.
a Median comparison using log-rank test and Kruskal-Wallis.
b Mean comparison using t-test and ANOVA variance analysis.
c Generalized linear model assuming gamma  family with log link.
Table 5
Multivariate analysis of efﬁciency and total costs as the dependent variables.
Cost Efﬁciency
Coefﬁcient (SD) p Coefﬁcient (SD) p
Ordinary least square regression
Intervention group 991.87 (938.40) 0.29 −0.0762 (0.0398) 0.06
Female −901.43 (1061.70) 0.40 0.0627 (0.045) 0.17
80  years old or older −346.20 (963.38) 0.72 −0.0653 (0.0408) 0.11
≥3  categories of chronic condition 1,194.98 (997.65) 0.23 −0.0631 (0.0422) 0.14
Baseline EQ-5D utility score −1.49 (1,309.02) 1.00 0.7595 (0.0552) < 0.001
Constant 4,922.93 (1,462.05) 0.001 0.1296 (0.0618) 0.038
Generalized linear model
Intervention group 0.2372 (0.1710) 0.17 −0.1076 (0.0715) 0.13
Female −0.1903 (0.1967) 0.33 0.1165 (0.0842) 0.17
80  years old or older −0.0671 (0.1751) 0.70 −0.1404 (0.0729) 0.05
≥3  categories of chronic condition 0.2589 (0.1901) 0.17 −0.0676 (0.0789) 0.39
Baseline EQ-5D utility score 0.0364 (0.2656) 0.99 2.0016 (0.1959) < 0.001
Constant 8.4504 (0.2831) < 0.001 −1.9685 (0.1965) < 0.001
Seemingly Unrelated Regression - Simple model
Intervention group 1,035.88 (925.26) 0.26 −0.0762 (0.0389) 0.05
Female −836.89 (1,050.39) 0.43 0.0627 (0.0442) 0.16
80  years old or older −310.11 (948.17) 0.74 −0.0653 (0.0399) 0.1
≥3  categories of chronic condition 1,165.43 (980.71) 0.24 −0.0631 (0.0412) 0.13
Baseline EQ-5D utility score 24.03 (1,285.34) 0.99 0.7595 (0.0540) < 0.001
Constant 4,880.80 (1,437.08) 0.1296 (0.0604)
Seemingly Unrelated Regression - Subgroup analysis
Intervention group 1,399.84 (1,534.25) 0.36 −0.0576 (0.0658) 0.38
Female −967.26 (1,039.54) 0.35 0.0594 (0.0446) 0.18
≥80  years of age −1,416.95 (1,326.30) 0.28 −0.0695 (0.0568) 0.22
≥3  categories of chronic condition 2,712.17 (1,351.01) 0.05 −0.0357 (0.0579) 0.54
Baseline EQ-5D utility score −36.35 (1,259.94) 0.98 0.7595 (0.0540) < 0.001
≥80  years * group 2,724.85 (1,838.22) 0.14 0.0170 (0.0788) 0.83
≥3  categories * group −3,475.84 (1,841.26) 0.06 −0.0567 (0.0789) 0.47
Constant 4,808.12 (1,583.84) 0.1467 (0.0654)
Difference, IG vs. CG (95%CI)a
Subgroup <80 years + 2 categories 1,399.84 (−1,704; 4,374) −0.0576 (−0.18; 0.06)
Subgroup <80 years + ≥3 categories −2,076.00 (−5,622; 1,189) −0.1143 (−0.27; 0.02)
Subgroup ≥80 years + 2 categories 4,124.69 (1,156; 6,980) −0.0406 (−0.18; 0.10)
Subgroup ≥80 years + ≥3 categories 648.85 (−2,775; 3,908) −0.0973 (−0.22; 0.03)
CG: control group; IC: intervention group; SD: standard deviation.
a 95% conﬁdence interval estimated using bootstrapping method.
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eneﬁts would be more likely to be seen with disease management
are models.
Authors that underline the importance of small changes in con-
inuity of care for decreasing costs, resource use and complications,
uch as Hussey et al.,18 indicate a potential limitation of their
esearch is that the ﬁndings might not extrapolate to younger popu-
ations, since it focused on adults over 65 years of age. In our study,
e did not consider age as an exclusion criterion and conclude that
he intervention could be more efﬁcient in those under 80 years of
ge.
The patients aged 80 years and over with three or more clini-
al categories of chronic conditions correspond to the apex of the
aiser pyramid. Besides healthcare (i.e., case management) they
equire coordination between social and healthcare services, giv-
ng priority to maintaining their independence as far as possible.16
uch patients do not beneﬁt from the evaluated model as it has no
mpact on quality of life or disease progression, and there are more
ssociated costs due to a higher use of healthcare resources. How-
ver, they may  beneﬁt from the use of care models for end-of-life
atients.17,19
Vondeling9 suggested that the general principles of economic
valuation can be adapted to the assessment of integrated care.
owever, a lack of evidence on efﬁcacy frequently hampers the
conomic evaluation of integrated care, contrasting with the wide
vailability of data on pharmacoeconomics. We  based our study
n a cluster randomized clinical trial providing a strong level of
vidence.10,20,21 The statistical analysis enabled us to identify a
ubgroup in which future studies should be carried out as the inter-
ention could be cost saving. Our results indicated that age, sex,
omorbidity, and baseline Barthel Index and EQ-5D scores had an
mpact on the QALYs in each group, which seems logical given
he level of multimorbidity, frailty and mortality in the sample. In
ddition to inﬂuencing perceived quality of life, in elderly people,
omorbidity and disability are negative prognostic factors for func-
ionality and survival. It should be taken into account that changes
t the organization level and in healthcare management have a
imited effect on the natural history of patients with high comor-
idity. As a consequence, we should not expect marked changes in
ealth outcomes.19
Literature shows that it is difﬁcult to obtain good results
n this population.22,23 However, our economic evaluation pro-
ided useful clues in terms of best suited target population to
e taken into account in the implementation of future integrated
rograms. Moreover, it was supported by strong evidence-based
esign (cluster randomized clinical trial) and patient-data level
tatistical analysis. We  have tried to solve the main three difﬁcul-
ies encountered by applying multivariante and subgroup analysis.
irst, complex patients tend to have a high level of multimorbidity.
atients with an average Charlson24 index of 5 have a 25% risk of
eath in the year of follow-up, masking any impact of the inter-
ention. Second, the multifaceted nature of the healthcare model
tself makes these types of intervention complex.25 Finally, we  are
ot dealing with a clinical intervention but rather changes at the
rganizational level and in patient management.
This study has enabled us to assess an integrated healthcare
odel in terms of cost-utility. Despite the intervention not being
fﬁcient, our results are relevant as they contradict the usual
ssumption that integrated care models increase efﬁciency and
uality of life, as well as leading to cost savings by decreasing
ospitalizations.8,18,26 Even though this study was  focused on an
verall analysis of patients with multimorbidity, the subgroup
nalysis carried out allowed us to identify a narrow target pop-
lation that should be analyzed in depth. Future research should
nvolve studying the results of implementing the model in patients
nder 80 years of age with high level of comorbidity. In the
ight of our results, it seems clear that there is a need for more2016;30(5):352–358 357
economic assessment studies to provide evidence on the efﬁciency
of integrated models, to support their widespread use in health
systems.
What is known about the topic?
The increasing prevalence of chronic diseases has led to
a profound change in multi-morbid patients care. Integrated
programs which include new roles for nurses and physicians
constitute the new paradigm but given their complex nature
their implementation is challenging and must be evaluated.
What does this study add to the literature?
The model assessed was not found to be cost-effective in
general. However, mean healthcare costs were lower for peo-
ple under 80 years of age with three or more clinical categories
of chronic conditions. Integrated interventions are not suitable
for all medically frail patients but rather for a subset that can
be identiﬁed by statistical analysis.
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